Showing 521 - 540 results of 800 for search '"Hepatocellular carcinoma"', query time: 0.08s Refine Results
  1. 521
  2. 522
  3. 523
  4. 524
  5. 525
  6. 526
  7. 527

    Stellettin B Isolated from Stelletta Sp. Reduces Migration and Invasion of Hepatocellular Carcinoma Cells through Reducing Activation of the MAPKs and FAK/PI3K/AKT/mTOR Signaling Pathways by Tsung-Chang Tsai, Wen-Tung Wu, Jen-Jie Lin, Jui-Hsin Su, Yu-Jen Wu

    Published 2022-01-01
    “…Hepatocellular carcinoma (HCC) is one of the most common malignant tumors, and there is currently a lack of effective treatment options to control the metastasis. …”
    Get full text
    Article
  8. 528

    The Prognostic Value of CRP/Alb Ratio in Predicting Overall Survival for Hepatocellular Carcinoma Treated with Transcatheter Intra-Arterial Therapy Combined with Molecular-Targeted Agents and PD-1/PD-L1 Inhibitors by Huang X, Peng G, Kong Y, Cao X, Zhou X

    Published 2025-01-01
    “…Xiaoyu Huang, Gang Peng, Yaqing Kong, Xiaojing Cao, Xiang Zhou Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of ChinaCorrespondence: Xiang Zhou, Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China, Email zhou.xiang@yeah.netPurpose: This study aimed to evaluate the prognostic value of C-reactive protein to albumin (CRP/Alb) ratio in hepatocellular carcinoma (HCC) treated with transcatheter intra-arterial therapy combined with molecular targeted agents (MTAs) and programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors.Methods: Medical records of 271 consecutive patients with HCC receiving this combination therapy in China between 2019 and 2023 were retrospectively analyzed. …”
    Get full text
    Article
  9. 529
  10. 530

    Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients by Shigeru Yutani, Kazuomi Ueshima, Kazumichi Abe, Atsushi Ishiguro, Junichi Eguchi, Satoko Matsueda, Nobukazu Komatsu, Shigeki Shichijo, Akira Yamada, Kyogo Itoh, Tetsuro Sasada, Masatoshi Kudo, Masanori Noguchi

    Published 2015-01-01
    “…To evaluate safety and immune responses of personalized peptide vaccination (PPV) for hepatitis C virus- (HCV-) positive advanced hepatocellular carcinoma (HCC). Patients and Methods. Patients diagnosed with HCV-positive advanced HCC were eligible for this study. …”
    Get full text
    Article
  11. 531
  12. 532
  13. 533
  14. 534
  15. 535
  16. 536
  17. 537
  18. 538
  19. 539
  20. 540

    Autoregulatory Feedback Mechanism of P38MAPK/Caspase-8 in Photodynamic Therapy-Hydrophilic/Lipophilic Tetra-α-(4-carboxyphenoxy) Phthalocyanine Zinc-Induced Apoptosis of Human Hepatocellular Carcinoma Bel-7402 Cells by Yu Wang, Chunhui Xia, Wei Chen, Yuhang Chen, Yiyi Wang, Tao Li

    Published 2014-01-01
    “…Our previous study showed that hydrophilic/lipophilic tetra-α-(4-carboxyphenoxy) phthalocyanine zinc- (TαPcZn-) mediated PDT (TαPcZn-PDT) inhibits the proliferation of human hepatocellular carcinoma Bel-7402 cells by triggering apoptosis and arresting cell cycle. …”
    Get full text
    Article